Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235074 | 0.94 | NR1I3 (0.34) | ACENR1I3KMT2ASIRT5LMNA | |
| SCHEMBL2234433 | 0.93 | NR1I3 (0.33) | ACENR1I3KMT2ANOTUMSIRT5 | |
| SCHEMBL2236269 | 0.92 | ACE (0.33) | ACENR1I3KMT2ASIRT5LMNA | |
| SCHEMBL2238186 | 0.92 | ACE (0.33) | ACENR1I3KMT2ASIRT5PPARG | |
| SCHEMBL2233980 | 0.90 | ACE (0.33) | ACENR1I3KMT2ASIRT5 | |
| SCHEMBL2234065 | 0.87 | NR1I3 (0.34) | ACENR1I3KMT2ALMNAPPARG | |
| SCHEMBL2236317 | 0.87 | ACE (0.34) | ACENR1I3 | |
| SCHEMBL2234511 | 0.86 | ACE (0.33) | ACENR1I3KMT2ASIRT5PPARG | |
| SCHEMBL2235348 | 0.85 | ACE (0.34) | ACENR1I3KMT2ASIRT5LMNA | |
| SCHEMBL2238348 | 0.85 | LMNA (0.39) | ACENR1I3KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | ACE 473/4885NR1I3 1315/4885KMT2A 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.